Clinical Trial Update: Open Label Extension Study of Brentuximab Vedotin in Early dcSSc [Phase 2]

View source ↗

Summary

Open-label extension study of Brentuximab Vedotin for early diffuse cutaneous systemic sclerosis; Phase 2, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Status: RECRUITING